Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.110

Lingying Wu , Ning Li , Jing Wang , Qingshui Li , Danbo Wang , Junying Tang , Cuiying Zhang , Guonan Zhang , Min Hao , Desheng Yao , Wei Duan , Qinglei Gao , Li Wang , Youzhong Zhang , Ruifang An , Rutie Yin , Qi Zhou , Hongying Yang , Jianqing Zhu , Kui Jiang , Bo Li

引用次数: 0

查看原文本刊更多论文

Fuzuloparib 作为一线铂类化疗反应后晚期卵巢癌患者的维持疗法：一项随机、安慰剂对照III期试验的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy